• 1. Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
  • 2. Division of Nephrology, Linfen Central Hospital, Linfen, Shanxi 041000, P. R. China;
ZHANG Ling, Email: zhangling-crrt@163.com
Export PDF Favorites Scan Get Citation

This article aims to interpret the consensus report of the 30th Acute Disease Quality Initiative (ADQI) workgroup on hemoadsorption (HA) technology, providing reference for clinical practice and research. HA has shown therapeutic advantages in various diseases. The ADQI workgroup assessed the research progress of HA technology, confirming its clinically acceptable short-term biocompatibility, safety, and technical feasibility, as well as experimental demonstration of specified target molecule removal. Preliminary studies have shown a potential benefit of endotoxin-based HA in sepsis. However, due to insufficient clinical evidence, HA is still considered an experimental intervention. The ADQI consensus report focuses on filling existing knowledge gaps, pointing out future research directions, and providing important guidance for the clinical application and further research of HA technology.

Citation: GUAN Mingjing, ZHANG Ling, PAN Hongju. Interpretation of Hemoadsorption: Consensus Report of the 30th Acute Disease Quality Initiative Workgroup. West China Medical Journal, 2024, 39(7): 1036-1040. doi: 10.7507/1002-0179.202406097 Copy

  • Previous Article

    Advances in anti-thrombogenetic strategies of biomaterials
  • Next Article

    Development and validation of prediction models for death in patients with rhabdomyolysis-induced acute kidney injury treated with continuous renal replacement therapy